Thus, although BET protein inhibitors seem a promising therapeutic strategy for the treatment of HNSCC with YAP/TAZ activation, more research is needed in the field before translating these advances into the clinical setting. This evidence concerns the gene DNER and head and neck squamous cell carcinoma.